Avantor Förvaltning
Förvaltning kriterier kontrolleras 2/4
Avantor VD är Emmanuel Ligner, utsedd i Aug 2025, har en mandatperiod på mindre än ett år. totala årliga ersättningen är $ 5.90M, bestående av 6.4% lön 93.6% bonusar, inklusive företagsaktier och optioner. äger direkt 0.013% av företagets aktier, värda $ 892.80K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2.4 år respektive 2.8 år.
Viktig information
Emmanuel Ligner
Verkställande direktör
US$5.9m
Total ersättning
| VD-lön i procent | 6.43% |
| Anställning som VD | less than a year |
| Ägande av VD | 0.01% |
| Ledningens genomsnittliga anställningstid | 2.4yrs |
| Styrelsens genomsnittliga mandatperiod | 2.8yrs |
Senaste uppdateringar av ledningen
Recent updates
Analysartikel • Jun 17
Avantor (AVTR) Stock Could Be 34% Below Fair Value After Wolfe Research Downgrade
Wolfe Research’s new Underperform rating on Avantor (AVTR) has put fresh attention on the stock, as the firm pointed to ongoing growth and margin pressures, as well as market share losses in its VWR distribution business. See our latest analysis for Avantor. Avantor’s recent 1 day share price return declined 1.44%, extending a 7 day share price return decline of 3.43%. However, the 30 day share price return rose 25.59%, while the 1 year total shareholder return declined 27.22%. This indicates...
Uppdatering av berättelse • Jun 15
AVTR: Compressed Margins And Shrinking Real Revenue Will Weigh On Future Returns
Analysts have trimmed the fair value estimate for Avantor to $7.00, reflecting a series of lower price targets and continued concerns about shrinking real revenue, margin compression, and execution risk, even though some expectations remain for improved growth and profitability over time. Analyst Commentary Recent Street research on Avantor has leaned cautious, with several bearish analysts cutting price targets and highlighting ongoing operational and profitability challenges.
Uppdatering av berättelse • Jun 01
AVTR: Reset Expectations And Quality Expansion Will Support Turnaround Execution And Repricing
Analysts have trimmed Avantor's fair value estimate by about $0.48 to $15.99, as recent price target cuts and concerns about execution, market share trends, and confidence in the turnaround story temper prior expectations. Analyst Commentary Street research on Avantor has centered on whether the current share price already reflects execution risk and the uncertainties around the turnaround plan.
Uppdatering av berättelse • May 01
AVTR: Reset Expectations And Execution Progress May Support Future Upside
Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.Seeking Alpha • Apr 30
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Summary Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks. Valuation screens as discounted, but low multiples reflect market skepticism about AVTR’s growth durability and margin structure; a hold rating is maintained pending clearer evidence of turnaround. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 16
AVTR: Expanded Quality Control Capabilities Will Support Execution Turnaround And Future Share Repricing
Analysts have trimmed their average price targets on Avantor, and the updated fair value estimate now stands at about $16.47. This reflects a softer sentiment around the stock as research notes point to share losses, reduced investment, and questions about management's ability to stabilize the business.Uppdatering av berättelse • Apr 02
AVTR: Reset Expectations And Share Repurchases May Support Future Upside
The analyst price target for Avantor has shifted lower to reflect a series of Street target cuts, including a move to $8.50. This change stems from concerns about share losses, constrained investment, and uncertainty over whether management can stabilize the business.Uppdatering av berättelse • Mar 19
AVTR: Execution Turnaround In Core Franchise Will Drive Future Share Repricing
Analysts have lowered their price targets on Avantor, with the updated fair value estimate moving from about $17.68 to $16.13 as they factor in concerns about share losses, underinvestment, and uncertainty around management's ability to stabilize the business, along with a higher assumed discount rate and P/E multiple. Analyst Commentary Recent Street research has tilted cautious on Avantor, highlighted by a downgrade to Underweight with a US$8.50 price target and several cuts to prior price targets.Uppdatering av berättelse • Mar 05
AVTR: Reset Expectations And Buybacks Will Support Future Upside Potential
Analysts have cut their average price target on Avantor by a few dollars to reflect lower fair value estimates, softer assumed revenue growth and profit margins, and a higher future P/E multiple in light of recent broad target reductions from firms across the Street. Several have moved targets in a $2 to $4 range, and one reset its view from $14 to $12.Analysartikel • Feb 13
The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%
Avantor, Inc. ( NYSE:AVTR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Uppdatering av berättelse • Feb 04
AVTR: Service Expansion And Execution Will Drive Upside From Reset Expectations
Narrative Update: Avantor Analyst Price Target Shift Analysts recently trimmed their price target on Avantor to $12 from $14. This reflects updated views on the life science tools sector and a Q4 outlook where many companies have already set softer expectations for 2026.Uppdatering av berättelse • Jan 21
AVTR: Share Repurchases And Execution Risks Will Shape Turnaround Visibility
Analysts have trimmed their price target on Avantor by about $0.60, reflecting more cautious assumptions on revenue growth and future P/E. This is partly offset by slightly higher profit margin expectations and a marginally lower discount rate.Uppdatering av berättelse • Jan 07
AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential
Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.Uppdatering av berättelse • Dec 14
AVTR: Share Repurchases Will Drive Upside As Turnaround Visibility Improves
Analysts have modestly lowered their price targets on Avantor by a few dollars per share, generally to the low to mid teens in dollar terms. They cite reduced guidance, weaker quarters and limited visibility around the company’s turnaround and strategic review.Uppdatering av berättelse • Nov 28
AVTR: Share Repurchase Initiative And Execution Will Shape Recovery Prospects Ahead
Analysts have lowered their price target for Avantor from $14 to $12 per share, citing a weak quarter, reduced guidance, and ongoing execution risks as primary concerns behind the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets ahead of quarterly results, reflecting improved confidence in Avantor’s long-term positioning despite current volatility.Uppdatering av berättelse • Nov 14
AVTR: Share Repurchase And Execution Will Define Turnaround Prospects In 2025
Avantor’s analyst price target has decreased from $13.80 to $13.64. Analysts cite reduced company guidance, execution risks, and ongoing uncertainty surrounding its earnings outlook as key factors driving the revision.Analysartikel • Nov 01
Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Avantor, Inc. ( NYSE:AVTR ) shares in the week since it released its third-quarter...Uppdatering av berättelse • Oct 31
AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery
Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.Analysartikel • Oct 28
There's No Escaping Avantor, Inc.'s (NYSE:AVTR) Muted Earnings Despite A 28% Share Price Rise
Avantor, Inc. ( NYSE:AVTR ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...Uppdatering av berättelse • Oct 16
Pharma Contracts And R&D Will Drive Growth Amid Price Pressures
Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.Analysartikel • Sep 12
We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysartikel • Aug 12
Concerns Surrounding Avantor's (NYSE:AVTR) Performance
NYSE:AVTR 1 Year Share Price vs Fair Value Explore Avantor's Fair Values from the Community and select yours Avantor...Seeking Alpha • Apr 26
Avantor: A Healthier Diagnosis As Expectations Cool
Summary Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio. The risk-reward profile has improved due to lower expectations, but the outlook remains cautious amidst continued sales declines and pending leadership changes. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Avantor: Mundane Business, Solid Cash Flow, Potential New Risks
Summary Avantor, Inc. has seen a significant decline in its stock price recently. The company did divest itself of one business this summer, paying down some debt with the proceeds. In addition, the company delivered an impressive amount of free cash flow in FY2024. Buy, Sell or Hold? An analysis around AVTR stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 18
Avantor: Durable FCF Generator Trading For Cheap
Summary Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor’s leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company’s capital structure and return value to shareholders. Potential industry inflection point creates optimal entry point with multiple expansion. Read the full article on Seeking AlphaSeeking Alpha • Oct 24
Avantor: Uninspiring, Even Amidst Some Green Shoots
Summary Avantor shares have struggled on the back of a high valuation, significant debt, and lackluster growth, despite recent improvements in organic sales and a divestment. The company operates two segments: a $4.7 billion laboratory solutions business, and a $2.2 billion bioscience production business, with the latter having higher margins. Recent financials show declining sales and earnings, amidst high valuation and a demanding valuation. A $650 million divestment aims to reduce debt, but the overall risk-reward remains unattractive given the company's past performance and high leverage. Read the full article on Seeking AlphaAnalys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$551m |
| Dec 31 2025 | US$6m | US$379k | -US$530m |
Ersättning vs marknad: Emmanuel s total kompensation ($USD 5.90M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 8.35M ).
Ersättning vs inkomst: Otillräcklig data för att jämföra Emmanuel s ersättning med företagets resultat.
VD OCH KONCERNCHEF
Emmanuel Ligner (55 yo)
less than a year
Anställning
US$5,895,624
Kompensation
Mr. Emmanuel Ligner is President and Chief Executive Officer of Avantor, Inc. from August 18, 2025 and serves as its Director. He was Chief Executive Officer of Cerba HealthCare S.A.S. from March 01, 2024...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| President | less than a year | US$5.90m | 0.013% $ 892.8k | |
| Executive VP | 3yrs | US$3.75m | 0.0033% $ 231.9k | |
| President of Laboratory Solutions | 2.1yrs | US$5.99m | 0.0033% $ 228.4k | |
| Executive Vice President of Bioscience Production | 2.8yrs | US$5.23m | 0.0036% $ 253.5k | |
| Senior VP | 7.2yrs | inga uppgifter | 0.019% $ 1.3m | |
| Executive VP & COO | less than a year | inga uppgifter | inga uppgifter | |
| Executive VP & Chief Information Officer | 8.3yrs | US$3.19m | inga uppgifter | |
| Vice President of Investor Relations | less than a year | inga uppgifter | inga uppgifter | |
| Executive VP & Chief Human Resources Officer | 2.9yrs | inga uppgifter | 0.036% $ 2.5m | |
| Executive Vice President of AMEA | 8.3yrs | inga uppgifter | 0.0088% $ 610.8k | |
| EVP of Bioscience & Medtech Products and Chief Transformation Officer | less than a year | inga uppgifter | inga uppgifter | |
| Executive Vice President of Quality & Regulatory | less than a year | inga uppgifter | inga uppgifter |
2.4yrs
Genomsnittlig anställningstid
56yo
Genomsnittlig ålder
Erfaren ledning: AVTR s ledningsgrupp anses vara erfaren ( 2.4 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| President | no data | US$5.90m | 0.013% $ 892.8k | |
| Independent Chairman of the Board | 6.2yrs | US$329.99k | 0.065% $ 4.5m | |
| Independent Director | less than a year | US$151.26k | 0.0088% $ 612.1k | |
| Independent Director | 1.7yrs | US$332.58k | 0.00070% $ 48.7k | |
| Independent Director | 4.7yrs | US$329.99k | 0.0051% $ 357.3k | |
| Chair of Scientific Advisory Board | 2.8yrs | US$3.09m | inga uppgifter | |
| Independent Director | 6.3yrs | US$324.99k | 0.0064% $ 442.9k | |
| Member of Scientific Advisory Board | 2.8yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 4.8yrs | US$317.49k | 0.0040% $ 276.5k | |
| Member of Scientific Advisory Board | 2.8yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 2.8yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 2.5yrs | inga uppgifter | inga uppgifter |
2.8yrs
Genomsnittlig anställningstid
61yo
Genomsnittlig ålder
Erfaren styrelse: AVTR s styrelse anses inte vara erfaren ( 2.8 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/08 20:03 |
| Aktiekurs vid dagens slut | 2026/07/08 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Avantor, Inc. bevakas av 27 analytiker. 16 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Charles Albert Dillard | Bernstein |